Minimize

Advertisement



ASCO Daily News > Top Headlines

Top Headlines

Continuous Androgen-Deprivation Therapy Remains Standard of Care for Metastatic Prostate Cancer

Therapeutic Landscape for Castrate- Resistant Prostate Cancer Still Evolving

Afatinib Prolongs Progression-Free Survival in NSCLC

Defining “Clinical Benefit” Presents Quandary When Selecting Trial Endpoints

Education Session Highlights Novel Approaches to Improve Cancer Care, Rein in Costs

MEK Inhibitor Trametinib to Expand Treatment Options for Patients with BRAF-Mutated Metastatic Melanoma

Patient Portals at Two Large Institutions Prove Successful for Oncology Practice

GRID Trial: Regorafenib Shows Promise for Patients with GIST

Education Session Focuses on Detection, Management of HPV-Related Head and Neck Cancer

SNRI Duloxetine Reduced Pain in Chemotherapy-Induced Peripheral Neuropathy

Education Sessions Examines Geographic Differences in Gastric Cancer Management, Outcomes

No Benefit from Addition of Gemcitabine to Dose-Dense AC in Operable, Node-Positive Breast Cancer

Emerging Science Pushing the Potential of Glioblastoma Therapy

In Brief

EMILIA: T-DM1 Demonstrates Greater Safety, Efficacy for Advanced HER2-Positive Breast Cancer

AOD Predictive Marker Established by Complementary Studies

Bendamustine Regimen More Effective, Better Tolerated Than Standard R-CHOP in Lymphoma

Dabrafenib Extends Progression-Free Survival in Metastatic Melanoma, Has High Clinical Activity in Brain Metastases

Studies Show Chest Radiation in Childhood Cancer Survivors Conferred Breast Cancer Risk Equal to BRCA1/2 Carriers

Abiraterone before Surgery Shows Promise for Patients with High-Risk Prostate Cancer in a Phase II Study

Education Session Highlights Progress toward Targeted, Individualized Therapy in CLL

Vitamin D Supplementation Viable for Reducing Pain during Breast Cancer Therapy

Glucocorticoid Reduced Cancer-Related Fatigue

Extended Use of Thiazolidinediones Associated with Increased Bladder Cancer Risk in Cohort Study

Study Reveals Diagnostic Value of FDG-PET with Non–Small Cell Lung Cancer Varies Widely

Education Session Offers Better Practices for Managing Medical Errors

Adjuvant Imatinib, Mutational Testing, Treatment in Relapsed Setting Discussed at GIST Education Session

Sexual Function Less Impaired with Intermittent Androgen-Deprivation

Tuesday In Brief

Intermittent AD Not Shown Noninferior to Continuous AD

Long-Term Follow-up of EORTC 26951 Study Confirms Benefit of Combined Therapy

Bendamustine Regimen More Effective, Better Tolerated than R-CHOP in Lymphoma

Trastuzumab Is Superior to Lapatinib as First-Line Therapy for HER2-Positive Metastatic Breast Cancer

Studies Report Progress in the Treatment of Advanced Ovarian Cancer

Investigational ALK Inhibitor LDK378 Highly Active in Crizotinib-Refractory ALK-Positive NSCLC

Promising Strategies for Ovarian Cancer Highlighted at Education Session

Genetic Sequencing May Shape Future of Clinical Trials, Cancer Therapy

Education Session Highlights Loco-regional Treatment Options for Breast Cancer

Traditional Monitoring Methods, Clinical Judgment

Observation May Be the Best Choice for Most Men with PSA-Detected Prostate Cancer

Navigating the Waters of Multiple Myeloma Induction, Transplant, and Maintenance

Maintenance Erlotinib Does Not Improve Ovarian Cancer Survival

More Effective Therapies Elusive in Esophageal Cancer

High-Dose BEACOPP Not Warranted for All Patients with High-Risk Hodgkin Lymphoma

Tivantinib Holds Promise for MET-Expressing Unresectable Hepatocellular Carcinoma

Chemotherapy Regimens Compared for Treatment of Active Follicular Lymphoma

Survey: PCPs Lack Knowledge of Late Effects of Common Chemotherapy Drugs

Curative-Intent Treatment of Colorectal Cancer

Understanding Income Barriers in Clinical Trial Participation is Needed to Improve Treatment, Outcomes

Clinical Benefits for Perifosine/Capecitabine Combination Not Realized in Phase III Study for Metastatic Colorectal Cancer

Data Support Using Lapatinib as a Component of Neoadjuvant Therapy for HER2-Operable Breast Cancer

Monday In Brief

Inhibition of PD-1 on T Cells

Studies Report Progress in the Treatment of Advanced Ovarian Cancer

PI3 Kinase Pathway Inhibitors Showing Activity in Multiple Cancer Types

PISCES: Patient-Reported Outcomes Indicate Pazopanib Preferred for Metastatic RCC

AFFIRM: Survival, Quality of Life, PSA Response Rates Favorable with Enzalutamide

Abiraterone Delays Progression in Patients with Chemotherapy-naïve CRPC

Phase I Trial: Targeted Therapy Safe in ALK-Positive Pediatric Cancers

New Molecular Targets Define Treatment in Non–Small Cell Lung Cancers

Adjuvant Therapy in Breast Cancer: Controversies Remain

Investigators Explore New Therapeutic Options for Metastatic Melanoma

As Molecular Head and Neck Cancer Discoveries Increase, Translation to Clinical Practice Vital

Sunday - In Brief

Clinical Practice Issues in Indolent Lymphomas Discussed at Education Session

The Economics of Lung Cancer

Education Session Tackles Question of Older Patients, Adjuvant Chemotherapy

Understanding the Rapidly Changing World of Melanoma Management

Minimally Invasive Surgery of Rectal Cancer: Current Evidence and Options

State Affiliates, Clinical Practice Committee Members Urge Congress to Protect Access to Cancer Care

Clinical Trials, Drug Development, Understanding of Biology of Cancer All Require Collaboration

ASCO Releases Clinical Evidence Review of Lung Cancer Screening

ASCO’s CancerLinQ™ Transforming Cancer Care through Real-time Learning

Editor's Welcome

Phase I Trials Have Ample Opportunity for Improvements

PARP Inhibitors Still Hold Promise for Breast Cancer, Despite Stumbling Blocks

Encouraging Lifestyle Modifications, Personalizing Surveillance Strategies Improves Risk of Second Cancer

Role of Biomarkers, Active Surveillance in Overdiagnosis and Overtreatment of Prostate Cancer

 ASCO President Dr. Michael P. Link Honors Friend, Touches Future through Philanthropy

Changing Times Bring Changes to Trial Design

Session Provides Insight, Supporting Research for New Cytotoxic Weight-based Dosing Standards

Education Session Provides Coping Strategies for Burnout, Stress, Grief

New Era in Lung Cancer Care: Personalized Medicine Brings Changing Roles for Researchers, Pathologists, Surgeons

Incidence, Prevalence of Chemotherapy- Induced Nausea and Vomiting Underestimated

Annual Meeting Education Program Incorporates NCI’s Provocative Questions

ASCO Daily News Now Features Newly Released Abstracts, Enhanced Program Information

Filling Global Needs: Interview with Dr. David Khayat

Multidisciplinary Focus Visible in All Aspects of the Annual Meeting Programs

The How & Why of Twitter

WebsiteFeedback